2023

Gliomatosis cerebri (GC) growth pattern: A single-center analysis of clinical, histological, and molecular characteristics of GC and non-GC glioblastoma
Divé I, Weber K, Hartung T, Steidl E, Wagner M, Hattingen E, Franz K, Fokas E, Ronellenfitsch M, Herrlinger U, Harter P, Steinbach J
NEURO-ONCOL ADV. 2023;5(1):vdad131.

DNA methylation subclasses predict the benefit from gross total tumor resection in IDH-wildtype glioblastoma patients
Drexler R, Schüller U, Eckhardt A, Filipski K, Hartung T, Harter P, Divé I, Forster M, Czabanka M, Jelgersma C, Onken J, Vajkoczy P, Capper D, Siewert C, Sauvigny T, Lamszus K, Westphal M, Dührsen L, Ricklefs F
NEURO-ONCOLOGY. 2023;25(2):315-325.

2021

Combination of Immune Checkpoint Inhibitors and Liver-Specific Therapies in Liver-Metastatic Uveal Melanoma: Can We Thus Overcome Its High Resistance?
Blomen C, Kött J, Hartung T, Torster L, Gebhardt C
CANCERS. 2021;13(24):.

DNA methylation-based prediction of response to immune checkpoint inhibition in metastatic melanoma
Filipski K, Scherer M, Zeiner K, Bucher A, Kleemann J, Jurmeister P, Hartung T, Meissner M, Plate K, Fenton T, Walter J, Tierling S, Schilling B, Zeiner P, Harter P
J IMMUNOTHER CANCER. 2021;9(7):.

Letzte Aktualisierung aus dem FIS: 17.07.2024 - 05:38 Uhr